ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pevonedistat. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

23 träffar

Bibliografisk träff 2019-10-30

Pevonedistat targeted therapy inhibits canine melanoma cell growth through induction of DNA re-replication and senescence.

Wood EA, Lu Z, Jia S, Assumpção ALFV, Van Hesteren MA, Huelsmeyer MK, Vail DM, Pan X.

Vet Comp Oncol · comparative study; research-article; journal article · DOI 10.1111/vco.12546

Bibliografisk träff 2019-09-04

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.

Faessel HM, Mould DR, Zhou X, Faller DV, Sedarati F, Venkatakrishnan K.

Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/bcp.14078

Bibliografisk träff 2019-05-22

MLN4924: additional activities beyond neddylation inhibition.

Zhou Q, Sun Y.

Mol Cell Oncol · research-article; journal article · DOI 10.1080/23723556.2019.1618174

Bibliografisk träff 2019-05-17

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.

Faessel H, Nemunaitis J, Bauer TM, Lockhart AC, Faller DV, Sedarati F, Zhou X, Venkatakrishnan K, Harvey RD.

Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1111/bcp.13915

Tillbakadragen publikation 2019-04-04

Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib.

Yang Z, Zhang J, Lin X, Wu D, Li G, Zhong C, Fang L, Jiang P, Yin L, Zhang L, Bie P, Xie CM.

Oncol Rep · retracted publication; research-article; journal article · DOI 10.3892/or.2019.7098

Bibliografisk träff 2019-03-09

Neddylation inhibitor MLN4924 suppresses cilia formation by modulating AKT1.

Mao H, Tang Z, Li H, Sun B, Tan M, Fan S, Zhu Y, Sun Y.

Protein Cell · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s13238-019-0614-3

Bibliografisk träff 2018-12-11

Disruption of protein neddylation with MLN4924 attenuates paclitaxel-induced apoptosis and microtubule polymerization in ovarian cancer cells.

Hong X, Li S, Li W, Xie M, Wei Z, Guo H, Wei W, Zhang S.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2018.12.048

Bibliografisk träff 2018-12-01

MRFAP1 plays a protective role in neddylation inhibitor MLN4924-mediated gastric cancer cell death.

Hu L, Bai ZG, Ma XM, Bai N, Zhang ZT.

Eur Rev Med Pharmacol Sci · journal article · DOI 10.26355/eurrev_201812_16524

Bibliografisk träff 2018-10-19

The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma.

Zhang W, Liang Y, Li L, Wang X, Yan Z, Dong C, Zeng MS, Zhong Q, Liu XK, Yu J, Sun S, Liu X, Kang J, Zhao H, Jeong LS, Zhang Y, Jia L.

Cell Prolif · research-article; journal article · DOI 10.1111/cpr.12536

Bibliografisk träff 2018-10-01

Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma.

Olaverria Salavaggione GN, Duggan MC, Carson WE.

Melanoma Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1097/cmr.0000000000000474

Bibliografisk träff 2018-04-17

A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.

Xu B, Deng Y, Bi R, Guo H, Shu C, Shah NK, Chang J, Liu G, Du Y, Wei W, Wang C.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1007/s00280-018-3582-z

Bibliografisk träff 2018-01-18

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.

Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, Pawlikowska-Dobler I, Faessel HM, Dash AB, Sedarati F, Dezube BJ, Faller DV, Savona MR.

Blood · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1182/blood-2017-09-805895

Bibliografisk träff 2017-08-24

The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors.

Vanderdys V, Allak A, Guessous F, Benamar M, Read PW, Jameson MJ, Abbas T.

Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-17-0083

Bibliografisk träff 2017-07-17

MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma.

Tong S, Si Y, Yu H, Zhang L, Xie P, Jiang W.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41598-017-06098-y

Bibliografisk träff 2017-06-01

Dissecting the Specificity of Adenosyl Sulfamate Inhibitors Targeting the Ubiquitin-Activating Enzyme.

Misra M, Kuhn M, Löbel M, An H, Statsyuk AV, Sotriffer C, Schindelin H.

Structure · journal article · DOI 10.1016/j.str.2017.05.001

Bibliografisk träff 2016-11-30

The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity.

Malhab LJ, Descamps S, Delaval B, Xirodimas DP.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/srep37775

Bibliografisk träff 2016-10-25

Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).

Wong KM, Micel LN, Selby HM, Tan AC, Pitts TM, Bagby SM, Spreafico A, Klauck PJ, Blakemore SJ, Smith PF, McDonald A, Berger A, Tentler JJ, Eckhardt SG.

Invest New Drugs · research-article; journal article · DOI 10.1007/s10637-016-0398-8

Bibliografisk träff 2016-04-01

MLN4924 therapy as a novel approach in cancer treatment modalities.

Oladghaffari M, Islamian JP, Baradaran B, Monfared AS.

J Chemother · review; journal article · DOI 10.1179/1973947815y.0000000066

Bibliografisk träff 2015-11-11

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.

Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S.

Clin Cancer Res · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-15-1237

Bibliografisk träff 2015-10-05

The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis.

Wolenski FS, Fisher CD, Sano T, Wyllie SD, Cicia LA, Gallacher MJ, Baker RA, Kirby PJ, Senn JJ.

Cell Death Discov · research-article; journal article · DOI 10.1038/cddiscovery.2015.34

Bibliografisk träff 2015-03-02

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.

Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, Hua Z, Blakemore SJ, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC.

Br J Haematol · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1111/bjh.13323

Bibliografisk träff 2010-01-01

Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.

Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, Soucy TA, Milhollen MA, Yang X, Burkhardt AL, Ma J, Loke HK, Lingaraj T, Wu D, Hamman KB, Spelman JJ, Cullis CA, Langston SP, Vyskocil S, Sells TB, Mallender WD, Visiers I, Li P, Claiborne CF, Rolfe M, Bolen JB, Dick LR.

Mol Cell · journal article · DOI 10.1016/j.molcel.2009.12.024

Bibliografisk träff 2009-04-01

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, Cullis CA, Doucette A, Garnsey JJ, Gaulin JL, Gershman RE, Lublinsky AR, McDonald A, Mizutani H, Narayanan U, Olhava EJ, Peluso S, Rezaei M, Sintchak MD, Talreja T, Thomas MP, Traore T, Vyskocil S, Weatherhead GS, Yu J, Zhang J, Dick LR, Claiborne CF, Rolfe M, Bolen JB, Langston SP.

Nature · journal article · DOI 10.1038/nature07884